Global News First-Line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefits in PD-L1+ NSCLC adminpost May 17, 2023 Eftilagimod alfa (efti; IMP321) plus pembrolizumab (Keytruda) provided overall survival (OS) benefit compared with...Read More
